| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Doravirine (JAN/USAN/INN); Pifeltro (TN) | ||||||||
| Abbr | DOR | ||||||||
| Product | PIFELTRO (Merck Sharp & Dohme LLC) | ||||||||
| Formula | C17H11ClF3N5O3 | ||||||||
| Exact mass | 425.0503 | ||||||||
| Mol weight | 425.7492 | ||||||||
| Structure |  | ||||||||
| Class | Antiviral DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI) DG03107 Anti-HIV agent DG01656 HIV reverse transcriptase inhibitor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate | ||||||||
| Remark |
| ||||||||
| Efficacy | Antiviral, Reverse transcriptase inhibitor | ||||||||
| Disease | HIV-1 infection [DS:H01563] | ||||||||
| Target | HIV-1 reverse transcriptase [KO:K24802] | ||||||||
| Pathway |
| ||||||||
| Metabolism | Enzyme: CYP3A [HSA:1576 1577 1551] | ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J05 ANTIVIRALS FOR SYSTEMIC USE J05A DIRECT ACTING ANTIVIRALS J05AG Non-nucleoside reverse transcriptase inhibitors J05AG06 Doravirine D10624 Doravirine (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Antivirals Anti-HIV Agents, Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Doravirine D10624 Doravirine (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 6 Agents against pathologic organisms and parasites 62 Chemotherapeutics 625 Antivirals 6250 Antivirals D10624 Doravirine (JAN/USAN/INN) Drug groups [BR:br08330] Antiviral DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI) D10624 Doravirine DG03107 Anti-HIV agent DG01656 HIV reverse transcriptase inhibitor D10624 Doravirine Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate D10624 Doravirine Drug classes [BR:br08332] Antiviral DG03107 Anti-HIV agent D10624 Doravirine Antimicrobials [BR:br08307] Antivirals Genome replication inhibitor HIV reverse transcriptase inhibitor D10624 Doravirine (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10624 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10624 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10624 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10624 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10624 | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 29 1 C8x C 14.2557 -16.0257 2 C8y C 14.2557 -17.3764 3 C8x C 15.4254 -18.0516 4 C8y C 16.5951 -17.3764 5 C8x C 16.5951 -16.0257 6 C8y C 15.4254 -15.3504 7 X Cl 15.4254 -13.9997 8 O2a O 17.7648 -18.0516 9 C8y C 18.9346 -17.3764 10 C8y C 20.0898 -18.0434 11 C8x C 21.2596 -17.3683 12 C8x C 21.2597 -16.0176 13 N4y N 20.1044 -15.3505 14 C8y C 18.9347 -16.0257 15 C1d C 20.0898 -19.3941 16 X F 18.7392 -19.3941 17 X F 21.4405 -19.3941 18 X F 20.0898 -20.7447 19 C1b C 20.1044 -13.9998 20 O5x O 17.7650 -15.3504 21 C3b C 13.0717 -18.0599 22 N3a N 11.8872 -18.7438 23 C8y C 21.3168 -13.2998 24 N4y N 22.6234 -13.8818 25 C8y C 23.5807 -12.8191 26 N4x N 22.8658 -11.5802 27 N5x N 21.4666 -11.8773 28 C1a C 22.9857 -15.2341 29 O5x O 24.9330 -13.1814 BOND 31 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 6 7 1 8 4 8 1 9 8 9 1 10 9 10 2 11 10 11 1 12 11 12 2 13 12 13 1 14 13 14 1 15 9 14 1 16 10 15 1 17 15 16 1 18 15 17 1 19 15 18 1 20 13 19 1 21 14 20 2 22 2 21 1 23 21 22 3 24 19 23 1 25 23 24 1 26 24 25 1 27 25 26 1 28 26 27 1 29 23 27 2 30 24 28 1 31 25 29 2 |